Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is testing a new gel treatment called Miltefosine to see if it can help heal skin sores caused by a disease called cutaneous leishmaniasis (CL). This disease causes skin wounds, and the study is looking at whether applying Miltefosine gel directly on these sores every day for 28 days is safe and helps the wounds get better. Researchers will try different strengths of the gel to find out which works best and whether it causes any skin problems.

Adults of any gender who have uncomplicated cutaneous leishmaniasis may be able to join the study. Before starting, participants will visit the clinic for tests and to learn about the study. They will apply the gel daily on their sores, take weekly photos, and keep track of any symptoms. Follow-up visits will happen after 28 days and again three months later to check progress. This is an early-stage study to see if this treatment should be tested further in larger trials.

Gender

ALL

Eligibility criteria